This case series reports an acute episode of hypoxemia and systemic hypotension in seven infants under 1 kg, taking place several hours or days after birth, after a period of stability and in the absence of significant lung disease. These patients were growth-restricted at birth and had a history of chronic fetal hypoxia and oligohydramnios. Pulmonary hypertension and right ventricular dysfunction were found by echocadiography. Right ventricular ejection fraction was significantly depressed during the acute episode, compared to baseline values measured after recovery. The timing of symptoms seemed related to ductus arteriosus closure or constriction. Oxygenation and right ventricular function improvement occurred within a few days under ventilatory and inotropic support, while milrinone was administered in five cases. In conclusion, pulmonary hypertension is a rare but significant cause of hypoxemia in preterm infants, and pulmonary vasodilator therapy should be considered in the presence of right ventricular dysfunction.
INTRODUCTION
Idiopathic pulmonary hypertension in the absence of significant lung disease is a rare finding in very low birth weight infants, in which hypoxemia typically results of surfactant deficiency, increased alveolar-arterial gradient, ventilation-perfusion mismatch and intrapulmonary shunting. 1 We report a series of seven premature infants with an extremely low birth weight who presented initially with a mild form of respiratory distress syndrome or no lung disease visible on chest radiograms, then, following a period of cardio-respiratory stability, had an acute hypoxemic and hypotensive episode. The echocardiograms, performed during the acute episode as part of the work-up, showed severe pulmonary hypertension and right ventricle (RV) dysfunction. The goals of this report are to describe the clinical and hemodynamic features of these patients, and to discuss the pathophysiology and the therapeutic implications of this condition.
PATIENTS AND METHODS
These cases were observed between December 1998 and December 2000 in two Harvard University-affiliated teaching centers in Boston, MA, USA. During that period, a total of 153 newborns <1 kg had been hospitalized, 49 of which had a birth weight <10th percentile for gestational age (32%). 2 Echocardiograms were performed with a Hewlett Packard Sonos 5500 cardiac scanner using transducers appropriate for patient size. The diagnosis of pulmonary hypertension was established on the basis of tricuspid regurgitant jet velocity or, when impossible, on the systolic configuration of the ventricular septum. RV pressure greater than half-systemic or a flattened septum were reported as ''moderate'', whereas RV pressure equal or superior to systemic or a septum bulging into the left ventricle were reported as ''severe''. 3 RV dysfunction was assessed qualitatively as ''mild'', ''moderate'' or ''severe''. RV ejection fraction was determined using a previously described technique based on standard two-dimensional echocardiograms, in which RV systolic and diastolic volumes are calculated using the formula: volume ¼ 2/3 area Â maximum length. 4 All ultrasound scans were reviewed by a single cardiologist (R.M.), who performed the morphological analyses and measurements. Each patient was used as his/her own control, by comparing data obtained during the acute episode with those after clinical improvement. Medical chart review was approved by the institutional review boards of the two hospitals. (Table 1) Three of the pregnancies were multiple. Routine fetal infection screenings were unremarkable, and there was no evidence of fetal malformations on morphological ultrasonograms. Signs of fetal distress, such as intrauterine growth restriction, decreased movements, nonreassuring heart rhythm or low 1-minute Apgar score were present in all cases. Pregnancy-induced hypertension, pre-eclampsia, oligohydramnios or reversed placental end-diastolic flow were reported in most, suggesting placental insufficiency as an etiology. All the infants were delivered by cesarean section. Five mothers (patients 3 to 7) had been treated with betamethasone prior to delivery. The median gestational age was 29±2.1 weeks, and the birth weight 655±132 g (median±SD). In the five cases where the placenta was examined, structural anomalies were noted.
RESULTS

Pre-and Perinatal History
Postnatal Clinical Course (Table 2 ) Six of the patients were intubated at birth and received surfactant within 6 hours. At 48 hours, four were extubated, while three were still receiving mild mechanical ventilation; all had a FiO 2 r30%. At this stage, despite echocardiographic signs of mild pulmonary hypertension, patients 1, 3 and 5 received indomethacin given the large size of the patent ductus arteriosus (PDA) and a predominantly left-to-right shunt. After a variable interval of stability (2 to 12 days from birth), all patients became abruptly hypoxemic and hypotensive. The PaO 2 /FiO 2 ratio decreased significantly (minus 40 to 76%). Chest radiograms at that time showed only minimal or no lung disease. Echocardiography was performed then (see below). Mechanical ventilation needed to be resumed or intensified, and vasopressors (dopamine, dobutamine) were used for a duration of 3 to 10 days (median: 4). Milrinone, a phosphodiesterase-III inhibitor, was used in five of the infants at a dosage of 0.25 to 0.75 mg/kg/min for a duration of 3 to 10 days, based on the presence of RV dysfunction. All patients improved substantially within 2 to 5 days. The PaO 2 /FiO 2 index increased gradually, and mechanical ventilation was weaned off in patients 1 to 6 within 5 to 44 days (median: 33). Patients 2 and 6 subsequently developed chronic lung disease and required oxygen therapy for 4 and 6 months, respectively. Two babies died: patient 6 at 5 months of age, out of respiratory syncytial virus infection, and patient 7 at 10 days after a brain hemorrhage.
Echocardiography Results (Table 2)
Prior to the hypoxemic event, between day 1 and 6 (median: 3), five infants had been examined by echocardiography because of a heart murmur, and had shown a PDA with either a bidirectional or left-to-right (L-R) shunt. At the onset of hypoxemia, all patients had evidence of pulmonary hypertension and global RV dysfunction. The RV ejection fraction was 13 to 40%, median: 28 (normal: 58 to 71 5 ). The ductus was closed in three of the five patients with a previous PDA, and had become restrictive with an inverted, right-to-left (R-L) shunt in two. In the two cases not checked before (2 and 6), the ductus was also closed. On follow-up echocardiograms performed 2 to 8 days after the onset of symptoms, signs of RV hypertension had disappeared in all cases except patient 3, and the RV ejection fraction had increased 1.2-to 3.6-fold. In patient 3, after 7 days the ductus was still patent, but with a reversed, L-R shunt, and was ultimately ligated at the age of 3 months; mild pulmonary hypertension persisted until 6 months. RV hypertrophy developed on patients 3 and 6, who were also found to have restricted pulmonary artery branches.
DISCUSSION
Premature infants with surfactant deficiency and severe respiratory distress syndrome may show persistently elevated RV pressures as a consequence of ventilation-perfusion mismatch and hypoxia-related lack of relaxation of the small pulmonary arteries. 6 However, clear, well-expanded lungs on chest radiograms and the delayed onset of symptoms after a period of stability make it unlikely in these cases. Conditions commonly associated with persistent pulmonary hypertension such as sepsis, perinatal asphyxia or meconium aspiration were not found. The acute symptoms observed in these infants, hypoxemia and hypotension, are suggestive of R-L shunting and cardiac output restriction. 7 None of the babies had ductal or interatrial shunts large enough to account for the degree of hypoxemia: five of the ducti were closed, and the other two were small. Therefore, hypoxemia resulted either from intrapulmonary shunting or decreased cardiac output. Systemic hypotension was likely the consequence of reduced left ventricle preload. 7 All except patient 4 had a birth weight <10th percentile, indicating intrauterine growth restriction (IUGR). In patient 4, despite a birth weight within normal range, fetal growth had decreased since 2 weeks prior to delivery. In the three cases born from multiple pregnancy, the birth weight was well <10th percentile even for twins standards. 8 Whereas there was no evidence of genetic disorders or fetal infections, several risk factors for uteroplacental insufficiency were present, such as placental anomalies, 9 maternal hypertension and pre-eclampsia, 10 decreased fetal/placental weight ratio and hypermature villi. 11 Uteroplacental insufficiency may lead to postnatal pulmonary hypertension by two mechanisms: oligohydramnios 12 and chronic fetal hypoxia. Indeed, five of our cases had oligohydramnios, only one of which related to P-PROM. Hypoxia increases endothelial synthesis of vasoconstrictors and smooth muscle mitogens such as endothelin-1, platelet-derived growth factor-b and vascular endothelial growth factor; it also inhibits endothelial nitric oxide synthase (eNOS). 13 In an animal model, hypoxia exposure in the perinatal period lead to increased RV pressure and abnormal pulmonary vascular reactivity in adulthood, related to permanent alterations of the eNOS pathway.
14 IUGR may be considered a hallmark of chronic fetal hypoxia: the direct relationship between umbilical venous and arterial oxygen saturation and birth weight has been well established in term infants. 10 Myocardial performance has been shown to deteriorate during the third trimester in IUGR fetuses, 15, 16 probably because of increased pulmonary resistance. All these considerations support the hypothesis that our patients, exposed to chronic intrauterine hypoxia, developed structural and functional alterations of the RV and the pulmonary vasculature, and were prone to develop pulmonary hypertension and right ventricular dysfunction.
The delayed deterioration after a period of stability seems to be triggered by a precipitating factor at some distance from birth. The five patients who had been examined by echocardiography prior to the deterioration all had a moderate or large PDA with L-R or bidirectional shunting. The repeat echocardiography after they had become symptomatic showed either a closed or a restrictive ductus with a R-L shunt. The short gap between ductal closure and the onset of pulmonary hypertension, as observed in patients 1, 4 and 7, suggests a cause-effect relationship between ductal closure and the hypoxemic event. In the two patients not examined before (2 and 6), the ductus was closed when hypoxemia occurred. In patient 2, the clinical deterioration occurred at 2 days, an expected timing for natural ductal closure in preterm infants. For patient 6, in whom hypoxemia occurred at 8 days, ductal closure might have been delayed by persistently elevated pulmonary resistances, as suggested by the RV hypertrophy observed for several weeks and severe pulmonary hypertension when he died at 5 months. Three of the patients had received indomethacin few hours prior to deteriorating. A similar observation was recently reported in three preterm infants treated with ibuprofen. 17 Cyclooxygenase (COX) inhibitors decrease the synthesis not only of prostaglandin E2, a major mediator of ductal patency, but also of prostacyclin, a potent pulmonary vasodilator. The ductus arteriosus is a dynamic structure during transitional circulation. It has been shown that, when pulmonary vascular resistance is still high, a L-R shunt through the ductus may increase significantly the pulmonary blood flow and contribute to oxygenation. 18 Conversely, when pulmonary arterial pressure is greater than systemic and the shunt reverts, the ductus may constitute a significant pressure relief to the RV afterload. 6 In our patients, the closure of this physiologic shunt may have triggered pulmonary vasoconstriction and restricted ventricular outputs, causing hypoxemia and hypotension.
Although several studies support the safety and efficacy of inhaled nitric oxide in preterm infants with respiratory distress syndrome. [19] [20] [21] [22] Inhaled nitric oxide was not approved for use in newborns under 34 weeks of gestation in our institutions at the time of these observations, mostly because of concerns regarding platelet inhibition. Milrinone, a phosphodiesterase-III inhibitor shown to improve right ventricular output in term neonates after cardiac surgery, 23 was used instead, given its inotrope and vasodilator properties. With respiratory and hemodynamic support plus milrinone in five cases, our patients gradually restored adequate RV function and pulmonary circulation.
Although growth restiction is frequently associated with prematurity F 30% of infants born <32 weeks have a birth weight <10th percentile of age-matched fetuses 24 F pulmonary hypertension is a rare event in these patients: we report seven cases out of a cohort of 153 infants, and three out of 135 are reported in the literature. 17 This retrospective case series clearly has inherent limitations. Besides the qualitative evaluation of RV function, we quantified RV volumes derived from two-dimensional measurements using a mathematical model. The appropriateness of this method, validated in children, was never established on preterm infants, but the percentage of improvement we calculated is likely to be accurate, since it was derived from comparison of each patient's data during the symptomatic episode and after recovery. Moreover, the RV ejection fraction values we report after stabilization (42 to 54%; median: 47) are close to those recently published in preterm infants. 5 More sophisticated methods for evaluating RV function and volume would be necessary. Although this study lacks the power for changing current clinical practices regarding the use of COX-inhibitors in growth-restricted babies, it supports a prompt and thorough evaluation of RV pressure and contractility in case of unexplained hypoxemia and/or hypotension. Our case study supports the use of pulmonary vasodilators in such conditions, that may permit to minimize ventilatory support escalation, but a clinical trial would be necessary to establish the efficacy and safety of milrinone in hypoxemic preterm infants with RV dysfunction.
